ReviewMediators of inflammation2015
Pathophysiological role of extracellular purinergic mediators in the control of intestinal inflammation.
Review in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- P2X4 purinergic receptor loss alters macrophage homeostasis, cytokine secretion, and phagocytosis in a myeloid-specific P2X4 purinergic receptor knockout mouse.Frontiers in immunology · 2026Article
- Article
- Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis.Inflammation · 2022Article
- The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers.International journal of molecular sciences · 2022Review
- Blocking pannexin1 reduces airway inflammation in a murine model of asthma.American journal of translational research · 2020Article
- Article
- Distributive differences of P2Xs between the forelimb and hind limb of adjuvant arthritis rats and intervention by Notopterygh rhizoma et radix.Pharmaceutical biology · 2019Article
- The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.Pharmacological reviews · 2019Review
- The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.Purinergic signalling · 2018Review
- Purinergic drug targets for gastrointestinal disorders.Current opinion in pharmacology · 2017Review
- Purinergic Signalling: Therapeutic Developments.Frontiers in pharmacology · 2017Review
- Blunted dynamics of adenosine A2A receptors is associated with increased susceptibility to Candida albicans infection in the elderly.Oncotarget · 2016Article
- P2X ion channel receptors and inflammation.Purinergic signalling · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purinergic mediators such as adenosine 5'-triphosphate (ATP) are released into the extracellular compartment from damaged tissues and activated immune cells. They are then recognized by multiple purinergic P2X and P2Y receptors. Release and recognition of extracellular ATP are associated with both the development and the resolution of inflammation and infection. Accumulating evidence has recently suggested the potential of purinergic receptors as novel targets for drugs for treating intestinal disorders, including intestinal inflammation and irritable bowel syndrome. In this review, we highlight recent findings regarding the pathophysiological role of purinergic mediators in the development of intestinal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.